IRWDIronwood Pharmaceuticals, Inc.
Is the price fair?
Cheap against its own history. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Cheap vs its own history: P/E 4.5 vs a 11.4 median over 19 quarters (−61% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IRWD's price assumes
Ironwood Pharmaceuticals, Inc. trades at 4.49× earnings against 21.0× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 21.0 · cheaper than the typical name in its group
- Price / sales
- 1.81
Price / sales · as of 2026-Q2
Details›
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - Specialty & Generic median P/E44 names
- 21.0
- Market capitalisation165.2 million shares, counted Jul 31, 2026
- $571M
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 4.49× today against a 11.4× median |
| 52-week range | $1.50 – $5.39 |
| Today | $3.46 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 39 by RyuScore